26 December 2023 in CHEST Pulmonary
Pulmonary nodules represent a growing health care burden because of delayed diagnosis of malignant lesions and overtesting for benign processes. Clinical prediction models were developed to inform physician assessment of pretest probability of nodule malignancy but have not been validated in a high-risk cohort of nodules for which biopsy was ultimately performed. Do guideline-recommended prediction models sufficiently discriminate between benign and malignant nodules when applied to cases referred for biopsy by navigational bronchoscopy? We assembled a prospective cohort of 322 indeterminate pulmonary nodules in 282 patients referred to a tertiary medical center for diagnostic navigational bronchoscopy between 2017 and 2019. We calculated the probability of malignancy for each nodule using the Brock model, Mayo Clinic model, and Veterans Affairs (VA) model. On a subset of 168 patients who also had PET-CT scans before biopsy, we also calculated the probability of malignancy using the Herder model. The performance of the models was evaluated by calculating the area under the receiver operating characteristic curves (AUCs) for each model. The study cohort contained 185 malignant and 137 benign nodules (57% prevalence of malignancy). The malignant and benign cohorts were similar in terms of size, with a median longest diameter for benign and malignant nodules of 15 and 16 mm, respectively. The Brock model, Mayo Clinic model, and VA model showed similar performance in the entire cohort (Brock AUC, 0.70; 95% CI, 0.64–0.76; Mayo Clinic AUC, 0.70; 95% CI, 0.64–0.76; VA AUC, 0.67; 95% CI, 0.62–0.74). For 168 nodules with available PET-CT scans, the Herder model had an AUC of 0.77 (95% CI, 0.68–0.85). Currently available clinical models provide insufficient discrimination between benign and malignant nodules in the common clinical scenario in which a patient is being referred for biopsy, especially when PET-CT scan information is not available.
1 December 2025 in Journal of the American College of Radiology
Lung cancer is the leading cause of cancer-related death in women. Lung cancer screening (LCS) uptake remains low despite clear scientific evidence of benefit and recommendations for screening from leading organizations. In a previous US study, 58% of LCS-eligible women reported having a mammogram within 2 years compared with only 7.9% who underwent LCS, suggesting an opportunity to improve LCS uptake. Mammography participants from November 2019 to December 2022 at two academic hospitals (site A and site B) were evaluated for potential LCS eligibility. Outreach was conducted to potentially eligible participants and referring providers to confirm eligibility and offer LCS. Women with metastatic malignancy or already enrolled in LCS were excluded. Historical enrollment rates at each site were used to predict successful implementation of enrollment strategies. Targeted outreach was performed for 12 months at each site. Of 32,165 mammography participants reviewed, 1,569 women (4.9%) were confirmed eligible with chart review for LCS and 1,089 of the 1,569 women (69%) had not previously undergone LCS. A significant increase in total LCS examinations among women during the study period was observed at both institutions. Baseline LCS scans in women increased from 12 and 28 scans per month at the two institutions, respectively, in the prestudy period to 18 and 38 scans per month during the study period (P = .0038 and .0125, respectively). There was no corresponding significant change in baseline LCS scans among men at either institution over the same time frame. Identifying women eligible for LCS through screening mammography programs is an opportunity to increase lung screening enrollment. The tactics employed identified women eligible for LCS from the screening mammography population and demonstrated a significant increase in LCS examinations in women.
30 October 2024 in CHEST Pulmonary
16 December 2022 in Cancer Epidemiology, Biomarkers & Prevention
Background: Indeterminate pulmonary nodules (IPN) are a diagnostic challenge in regions where pulmonary fungal disease and smoking prevalence are high. We aimed to determine the impact of a combined fungal and imaging biomarker approach compared with a validated prediction model (Mayo) to rule out benign disease and diagnose lung cancer. Methods: Adults ages 40 to 90 years with 6–30 mm IPNs were included from four sites. Serum samples were tested for histoplasmosis IgG and IgM antibodies by enzyme immunoassay and a CT-based risk score was estimated from a validated radiomic model. Multivariable logistic regression models including Mayo score, radiomics score, and IgG and IgM histoplasmosis antibody levels were estimated. The areas under the ROC curves (AUC) of the models were compared among themselves and to Mayo. Bias-corrected clinical net reclassification index (cNRI) was estimated to assess clinical reclassification using a combined biomarker model. Results: We included 327 patients; 157 from histoplasmosis-endemic regions. The combined biomarker model including radiomics, histoplasmosis serology, and Mayo score demonstrated improved diagnostic accuracy when endemic histoplasmosis was accounted for [AUC, 0.84; 95% confidence interval (CI), 0.79–0.88; P < 0.0001 compared with 0.73; 95% CI, 0.67–0.78 for Mayo]. The combined model demonstrated improved reclassification with cNRI of 0.18 among malignant nodules. Conclusions: Fungal and imaging biomarkers may improve diagnostic accuracy and meaningfully reclassify IPNs. The endemic prevalence of histoplasmosis and cancer impact model performance when using disease related biomarkers. Impact: Integrating a combined biomarker approach into the diagnostic algorithm of IPNs could decrease time to diagnosis.
29 May 2024 in CHEST Pulmonary